5366-53-0

Usage

General Description

6-oxo-6-(4-phenylphenyl)hexanoic acid is a chemical compound with a unique structure that combines a hexanoic acid backbone with a 4-phenylphenyl group and a ketone functional group. It likely exhibits characteristics of both carboxylic acids and ketones, impacting its chemical properties and potential applications. The presence of the phenylphenyl group introduces aromaticity, which can influence the compound's reactivity and behavior in various reactions.

InChI:InChI=1/C18H18O3/c19-17(8-4-5-9-18(20)21)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-3,6-7,10-13H,4-5,8-9H2,(H,20,21)

Upstream product

• 61454-89-5 methyl-6-(4'-biphenylyl)-6-keto hexanoate 
• 94958-92-6 4-Biphenylyl-<1-brom-cyclopentyl>-keton 
• 92-52-4 biphenyl 
• 35444-44-1 methyl adipoyl chloride 
• 93877-05-5 4-Biphenylyl-cyclopentyl-keton 
• 79-34-5 1,1,2,2-tetrachloroethane 
• 124-04-9 Adipic acid 
• 2035-75-8 adipic anhydride 
• 93877-01-1 2-((1,1'-biphenyl)-4-yl)cyclohexan-1-one 
• 5122-94-1 4-biphenylboronic acid 
• 822-87-7 2-Chlorocyclohexanone 

Downstream Products

• 1356067-68-9 2-(benzyloxy)-1-[(benzyloxy)methyl]ethyl 6-(1,1'-biphenyl-4-yl)hexanoate 

Relevant academic research and scientific papers

Selective C-C Bond Cleavage of Cycloalkanones by NaNO2/HCl

A novel selective fragmentation of cycloalkanones by NaNO2/HCl has been established. The C-C bond cleavage reaction proceeds smoothly under mild conditions, selectively affording versatile keto acids or oxime acids. The methodology can streamline the synthesis of valuable chiral molecules and isocoumarins from readily available feedstocks.

Structure-activity relationship of a new series of reversible dual monoacylglycerol lipase/fatty acid amide hydrolase inhibitors

The two endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), play independent and nonredundant roles in the body. This makes the development of both selective and dual inhibitors of their inactivation an important priority. In this work we report a new series of inhibitors of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH). Among them, (±)-oxiran-2-ylmethyl 6-(1,1′-biphenyl-4-yl)hexanoate (8) and (2R)-(-)-oxiran-2-ylmethyl(4-benzylphenyl)acetate (30) stand out as potent inhibitors of human recombinant MAGL (IC50 (8) = 4.1 μM; IC 50 (30) = 2.4 μM), rat brain monoacylglycerol hydrolysis (IC 50 (8) = 1.8 μM; IC50 (30) = 0.68 μM), and rat brain FAAH (IC50 (8) = 5.1 μM; IC50 (30) = 0.29 μM). Importantly, and in contrast to the other previously described MAGL inhibitors, these compounds behave as reversible inhibitors either of competitive (8) or noncompetitive nature (30). Hence, they could be useful to explore the therapeutic potential of reversible MAGL inhibitors.

4-aryl piperidines

This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

Substituted phenylalkenoic acids and esters

Substituted phenylalkenoic acids and esters of the formula: STR1 having useful pharmaceutical activity are disclosed.

Process for preparing substituted phenylalkenoic acids

Substituted phenylalkenoic acids and esters of the formula: STR1 having useful pharmaceutical activity and processes for their preparation are disclosed.